

Paul M Barr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7053054/publications.pdf>

Version: 2024-02-01

222
papers

11,574
citations

50276

46
h-index

30087

103
g-index

226
all docs

226
docs citations

226
times ranked

8791
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
2	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	27.0	1,261
3	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
4	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
5	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	27.0	545
6	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
7	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	7.2	321
8	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	10.7	314
9	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	4.1	305
10	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
11	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose+Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
12	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016, 127, 1559-1563.	1.4	228
13	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	1.4	178
14	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	1.4	177
15	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016, 128, 2199-2205.	1.4	166
16	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
17	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016, 127, 2411-2415.	1.4	131
18	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	1.6	120

#	ARTICLE	IF	CITATIONS
19	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	1.4	111
20	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	3.5	111
21	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 2915-2922.	1.4	104
22	The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2012, 120, 686-686.	1.4	99
23	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
24	Long-term outcomes for ibrutinib+rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	1.4	93
25	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	5.2	91
26	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.2	90
27	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	1.4	86
28	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	1.4	83
29	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
30	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
31	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	1.4	68
32	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e295-e298.	3.5	67
33	Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 971-978.	4.1	63
34	Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. <i>American Journal of Hematology</i> , 2009, 84, 484-487.	4.1	62
35	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 648-657.e15.	0.4	62
36	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	1.4	61

#	ARTICLE	IF	CITATIONS
37	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
38	Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018, 59, 625-632.	1.3	57
39	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	3.4	57
40	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	2.5	55
41	Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. <i>Cell Death and Differentiation</i> , 2010, 17, 1381-1391.	11.2	54
42	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
43	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
44	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 297-306.	2.6	51
45	Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1769-1773.	7.2	49
46	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	1.4	48
47	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013, 24, 3076-3081.	1.2	45
48	Phase 1 study of the PI3K γ inhibitor INCB040093 \pm JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. <i>Blood</i> , 2018, 132, 293-306.	1.4	45
49	Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 970-978.	2.0	42
50	RB but not R \pm HCVAD is a feasible induction regimen prior to auto \pm HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	2.5	40
51	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	1.4	40
52	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
53	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	3.7	36
54	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	1.4	36

#	ARTICLE	IF	CITATIONS
55	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.4	35
56	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 1259-1265.	1.4	34
57	How I treat early-relapsing follicular lymphoma. <i>Blood</i> , 2019, 133, 1540-1547.	1.4	33
58	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
59	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013, 122, 525-525.	1.4	32
60	The Role of Bortezomib in the Treatment of Lymphoma. <i>Cancer Investigation</i> , 2007, 25, 766-775.	1.3	29
61	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	3.8	29
62	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. <i>Leukemia</i> , 2021, 35, 1788-1791.	7.2	29
63	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	1.4	29
64	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1630-1630.	1.4	29
65	Zilvertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. , 2022, 1, .		28
66	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	4.1	27
67	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019, 104, 2258-2264.	3.5	26
68	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
69	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	1.4	26
70	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
71	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	1.4	24
72	Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 2383-2389.	1.3	23

#	ARTICLE	IF	CITATIONS
73	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	6.3	23
74	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. Blood, 2016, 128, 3705-3705.	1.4	23
75	Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British Journal of Haematology, 2009, 147, 89-96.	2.5	22
76	Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 323-326.	4.9	22
77	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Advances, 2022, 6, 4553-4557.	5.2	22
78	Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clinical Immunology, 2012, 142, 237-242.	3.2	21
79	Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leukemia and Lymphoma, 2016, 57, 635-643.	1.3	21
80	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.6	20
81	Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2021, 39, 7523-7523.	1.6	20
82	Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 41-47.	0.4	19
83	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. British Journal of Haematology, 2020, 188, 918-923.	2.5	19
84	Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.. Journal of Clinical Oncology, 2012, 30, 6515-6515.	1.6	19
85	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 535-546.	3.8	19
86	Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leukemia Research, 2011, 35, e223-e224.	0.8	18
87	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Cancer Medicine, 2016, 5, 3059-3067.	2.8	18
88	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances, 2019, 3, 3132-3135.	5.2	18
89	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	1.4	18
90	Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia and Lymphoma, 2007, 48, 1940-1949.	1.3	17

#	ARTICLE	IF	CITATIONS
91	Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 71, 43-46.	0.8	17
92	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. <i>British Journal of Haematology</i> , 2019, 186, 255-262.	2.5	17
93	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7501-7501.	1.6	16
94	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	1.4	16
95	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16
96	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. <i>Oncotarget</i> , 2017, 8, 79864-79875.	1.8	15
97	Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat. <i>Neuroscience Letters</i> , 1997, 230, 81-84.	2.1	13
98	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	1.4	13
99	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020, 136, 39-41.	1.4	13
100	Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8032-8032.	1.6	13
101	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019, 185, 961-966.	2.5	12
102	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
103	Treatment of chronic lymphocytic leukemia in older adults. <i>Journal of Geriatric Oncology</i> , 2017, 8, 315-319.	1.0	11
104	Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020, 61, 1627-1635.	1.3	11
105	A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 360-360.	1.4	11
106	Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7519-7519.	1.6	11
107	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7510-7510.	1.6	11
108	Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. <i>Current Opinion in Oncology</i> , 2008, 20, 502-508.	2.4	10

#	ARTICLE	IF	CITATIONS
109	Recent advances in the development of Aurora kinases inhibitors in hematological malignancies. Therapeutic Advances in Hematology, 2015, 6, 282-294.	2.5	10
110	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 186, 184-188.	2.5	10
111	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood, 2014, 124, 1990-1990.	1.4	10
112	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood, 2015, 126, 719-719.	1.4	10
113	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. Journal of Clinical Oncology, 2016, 34, 7520-7520.	1.6	10
114	Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 145-151.	0.4	9
115	Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. British Journal of Haematology, 2019, 186, 175-180.	2.5	9
116	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 2016, 128, 2042-2042.	1.4	9
117	Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, 7059-7059.	1.6	9
118	A phase 1 study of INCB040093, a PI3K inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. Journal of Clinical Oncology, 2015, 33, 8558-8558.	1.6	9
119	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology, 2023, 41, 336-342.	1.6	9
120	Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. Journal of Geriatric Oncology, 2011, 2, 215-221.	1.0	8
121	Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 781-787.	0.4	8
122	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 2020, 106, 284-287.	3.5	8
123	Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. American Journal of Hematology, 2020, 95, E108-E110.	4.1	8
124	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. Blood, 2015, 126, 2744-2744.	1.4	8
125	Correlation between ZAP70, phospho-ZAP70, and phospho-Syk expression in leukemic cells from patients with CLL. Cytometry Part B - Clinical Cytometry, 2010, 78B, 115-122.	1.5	7
126	Non-Hodgkin's Lymphoma in the Elderly. Drugs and Aging, 2010, 27, 211-238.	2.7	7

#	ARTICLE	IF	CITATIONS
127	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	1.3	7
128	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	1.4	7
129	Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2020, 188, e33-e36.	2.5	6
130	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
131	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6
132	Interim analysis of a phase I study of INCBO40093, a PI3K γ inhibitor, alone or in combination with INCBO39110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8520-8520.	1.6	6
133	Acalabrutinib combined with PI3K γ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7518-7518.	1.6	6
134	Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 322-328.e2.	0.4	5
135	Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e123-e127.	0.4	5
136	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018, 103, e249-e251.	3.5	5
137	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	3.5	5
138	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 518-518.	1.4	5
139	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K γ inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7530-7530.	1.6	5
140	Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 367-383.	2.4	4
141	Deregulation of NF- κ B, ie, a useful PMBL marker. <i>Blood</i> , 2016, 128, 2591-2592.	1.4	4
142	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019, 60, 3569-3572.	1.3	4
143	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. <i>Blood</i> , 2018, 132, 1691-1691.	1.4	4
144	Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. <i>Blood</i> , 2019, 134, 797-797.	1.4	4

#	ARTICLE	IF	CITATIONS
145	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
146	Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020, 136, 45-45.	1.4	4
147	Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma. <i>Blood</i> , 2014, 124, 5389-5389.	1.4	4
148	A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. <i>Blood</i> , 2015, 126, 3931-3931.	1.4	4
149	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	1.4	4
150	U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8523-8523.	1.6	4
151	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7519-7519.	1.6	4
152	Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, e123-e125.	1.2	3
153	Novel agents in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 191-200.	1.7	3
154	Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 508-511.	1.3	3
155	Complete recovery of late onset progressive multifocal leukoencephalopathy related to treatment with chemoimmunotherapy: A case report. <i>Leukemia Research</i> , 2020, 90, 106309.	0.8	3
156	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	1.4	3
157	Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 153-153.	1.6	3
158	Flavopiridol: Judged by the company one keeps. <i>Leukemia Research</i> , 2013, 37, 1187-1188.	0.8	2
159	Long-term safety experience with bendamustine for injection in a real-world setting. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 647-650.	2.4	2
160	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	4.1	2
161	Early Progression of Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 757-769.	2.2	2
162	Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)., 2017, , .		2

#	ARTICLE	IF	CITATIONS
163	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
164	High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors. <i>Blood</i> , 2016, 128, 3203-3203.	1.4	2
165	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	1.4	2
166	Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11584-11584.	1.6	2
167	Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2019, 134, 3054-3054.	1.4	2
168	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. <i>Haematologica</i> , 2022, 107, 1460-1465.	3.5	2
169	Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1728-1732.	1.3	2
170	Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATEâ„¢ (PCYC-1112) Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S204.	0.4	1
171	Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve. <i>Lancet Haematology</i> , 2017, 4, e152-e153.	4.6	1
172	Pitfalls of Combining Novel Agents in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 35.	3.0	1
173	Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S303.	0.4	1
174	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	2.7	1
175	Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1636-1644.	1.3	1
176	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	1.3	1
177	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	1.4	1
178	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	1.4	1
179	Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice. <i>Blood</i> , 2019, 134, 682-682.	1.4	1
180	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. <i>Blood</i> , 2012, 120, 1640-1640.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. Blood, 2014, 124, 3984-3984.	1.4	1
182	A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. Journal of Clinical Oncology, 2015, 33, TPS8607-TPS8607.	1.6	1
183	A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).. Journal of Clinical Oncology, 2016, 34, TPS7576-TPS7576.	1.6	1
184	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. Journal of Clinical Oncology, 2019, 37, 7510-7510.	1.6	1
185	Abstract 3531: Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR).. , 2013, , .		1
186	Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. Journal of Clinical Oncology, 2017, 35, 7543-7543.	1.6	1
187	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 2018, 132, 4759-4759.	1.4	1
188	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. Journal of Clinical Oncology, 2020, 38, 8038-8038.	1.6	1
189	Arrhythmia Burden in Patients with Indolent Lymphoma. Blood, 2020, 136, 6-7.	1.4	1
190	Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1166-1167.	1.3	0
191	Infection in chronic lymphocytic leukemia: parsimony has its limits. Leukemia and Lymphoma, 2014, 55, 2683-2684.	1.3	0
192	The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management. Leukemia and Lymphoma, 2014, 55, 1219-1220.	1.3	0
193	Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S24.	0.4	0
194	Efficacy in the margins of NHL with ibrutinib. Blood, 2017, 129, 2207-2208.	1.4	0
195	Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S304.	0.4	0
196	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S274.	0.4	0
197	Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab. Journal of Clinical Oncology, 2019, 37, 1151-1153.	1.6	0
198	Pharmacology of Acute Lymphoblastic Leukemia Therapy. , 2011, , 127-144.		0

#	ARTICLE	IF	CITATIONS
199	The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 8080-8080.	1.6	0
200	Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2882-2882.	1.4	0
201	Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study. Blood, 2013, 122, 89-89.	1.4	0
202	Adult Burkitt Lymphoma and Leukemia. , 2014, , 171-194.		0
203	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 3999-3999.	1.4	0
204	Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. Blood, 2014, 124, 1746-1746.	1.4	0
205	Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801. Blood, 2016, 128, 614-614.	1.4	0
206	Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting. Blood, 2016, 128, 5591-5591.	1.4	0
207	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. Journal of Clinical Oncology, 2017, 35, TPS7569-TPS7569.	1.6	0
208	Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. Journal of Clinical Oncology, 2017, 35, 6536-6536.	1.6	0
209	CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.. Journal of Clinical Oncology, 2017, 35, TPS7577-TPS7577.	1.6	0
210	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	1.6	0
211	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. Journal of Clinical Oncology, 2018, 36, 7521-7521.	1.6	0
212	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1593-1593.	1.4	0
213	Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.. Journal of Clinical Oncology, 2019, 37, 7547-7547.	1.6	0
214	High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.. Journal of Clinical Oncology, 2019, 37, e19058-e19058.	1.6	0
215	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. Blood, 2019, 134, 3048-3048.	1.4	0
216	Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.. Journal of Clinical Oncology, 2020, 38, 8035-8035.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	1.4	0
218	Real-world practice patterns in follicular lymphoma (FL) care at community oncology centers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 231-231.	1.6	0
219	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22.	1.4	0
220	Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 11, 17-19.	0.3	0
221	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1580-1588.	1.3	0
222	Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study. <i>Cancer Research</i> , 2022, 82, CT028-CT028.	0.9	0